Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rubius Therapeutics Inc (RUBY)

Rubius Therapeutics Inc (RUBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,158
  • Shares Outstanding, K 90,483
  • Annual Sales, $ 0 K
  • Annual Income, $ -179,670 K
  • 60-Month Beta 2.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.34
Trade RUBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.44
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 01/03/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 341.28%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +172,341.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0181 +214.92%
on 12/01/23
0.0570 unch
on 12/29/23
+0.0380 (+200.00%)
since 11/29/23
3-Month
0.0162 +251.85%
on 10/09/23
0.0570 unch
on 12/29/23
+0.0408 (+251.85%)
since 09/29/23
52-Week
0.0032 +1,681.25%
on 09/25/23
0.3763 -84.85%
on 02/14/23
-0.1354 (-70.37%)
since 12/29/22

Most Recent Stories

More News
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 20.04 (-0.25%)
EVLO : 0.0560 (-18.60%)
FHTX : 6.03 (+1.69%)
MRNA : 103.29 (-0.93%)
OMGA : 3.49 (-0.85%)
RUBY : 0.0570 (+2.70%)
SANA : 8.40 (-5.72%)
MCRB : 0.7912 (+4.34%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 20.04 (-0.25%)
EVLO : 0.0560 (-18.60%)
FHTX : 6.03 (+1.69%)
MRNA : 103.29 (-0.93%)
OMGA : 3.49 (-0.85%)
RUBY : 0.0570 (+2.70%)
SANA : 8.40 (-5.72%)
MCRB : 0.7912 (+4.34%)
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial...

RUBY : 0.0570 (+2.70%)
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.0570 (+2.70%)
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

/PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the...

RUBY : 0.0570 (+2.70%)
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting

Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens...

RUBY : 0.0570 (+2.70%)
Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer

Flagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined...

DNLI : 20.04 (-0.25%)
EVLO : 0.0560 (-18.60%)
FHTX : 6.03 (+1.69%)
MRNA : 103.29 (-0.93%)
OMGA : 3.49 (-0.85%)
RUBY : 0.0570 (+2.70%)
SANA : 8.40 (-5.72%)
MCRB : 0.7912 (+4.34%)
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.0570 (+2.70%)
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.0570 (+2.70%)
Flagship Pioneering Unveils ProFoundâ„¢ Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potential to Enable a Multitude of New Medicines

Flagship Pioneering, the bioplatform innovation company, today unveiled ProFoundâ„¢ Therapeutics, a company that has identified a universe of previously undiscovered human proteins, enabling a multitude...

DNLI : 20.04 (-0.25%)
EVLO : 0.0560 (-18.60%)
FHTX : 6.03 (+1.69%)
MRNA : 103.29 (-0.93%)
OMGA : 3.49 (-0.85%)
RUBY : 0.0570 (+2.70%)
SANA : 8.40 (-5.72%)
MCRB : 0.7912 (+4.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.0597
2nd Resistance Point 0.0583
1st Resistance Point 0.0577
Last Price 0.0570
1st Support Level 0.0557
2nd Support Level 0.0543
3rd Support Level 0.0537

See More

52-Week High 0.3763
Fibonacci 61.8% 0.2338
Fibonacci 50% 0.1898
Fibonacci 38.2% 0.1457
Last Price 0.0570
52-Week Low 0.0032

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar